Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for Dyskeratosis Congenita or Severe Aplastic Anemia
NCT02162420Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2015
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial in dyskeratosis congenita (DC) and aplastic anemia (5 arms), sponsored by Masonic Cancer Center. Primary endpoints: Incidence of Neutrophil Engraftment at Day 42 and Incidence of Platelet Engraftment at 1 year. Started Jan 2015; status: completed.
02
Conditions
dyskeratosis congenita (DC)aplastic anemia
Beyond the preview
Go deeper on NCT02162420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162420.